Terms: = Lung cancer AND CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1 AND Diagnosis
6 results:
1. Plasma exchange treats severe intrahepatic cholestasis caused by dacomitinib: A case report.
Qiao F; Chen Q; Lu W; Fang N
Medicine (Baltimore); 2022 Jul; 101(27):e29629. PubMed ID: 35801736
[TBL] [Abstract] [Full Text] [Related]
2. Impact of smoking on metabolic changes and effectiveness of drugs used for lung cancer.
Perlík F
Cent Eur J Public Health; 2020 Mar; 28(1):53-58. PubMed ID: 32228818
[TBL] [Abstract] [Full Text] [Related]
3. Genetic polymorphisms of phase I and phase II metabolic enzymes as modulators of lung cancer susceptibility.
Mota P; Silva HC; Soares MJ; Pego A; Loureiro M; Cordeiro CR; Regateiro FJ
J Cancer Res Clin Oncol; 2015 May; 141(5):851-60. PubMed ID: 25388590
[TBL] [Abstract] [Full Text] [Related]
4. cyp2d6 genotype and lung cancer risk according to histologic type and tobacco exposure.
Stücker I; Cosme J; Laurent P; Cenée S; Beaune P; Bignon J; Depierre A; Milleron B; Hémon D
Carcinogenesis; 1995 Nov; 16(11):2759-64. PubMed ID: 7586196
[TBL] [Abstract] [Full Text] [Related]
5. diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility--a review.
Raunio H; Husgafvel-Pursiainen K; Anttila S; Hietanen E; Hirvonen A; Pelkonen O
Gene; 1995 Jun; 159(1):113-21. PubMed ID: 7607565
[TBL] [Abstract] [Full Text] [Related]
6. Measurement of 4-aminobiphenyl-hemoglobin adducts in lung cancer cases and controls.
Weston A; Caporaso NE; Taghizadeh K; Hoover RN; Tannenbaum SR; Skipper PL; Resau JH; Trump BF; Harris CC
Cancer Res; 1991 Oct; 51(19):5219-23. PubMed ID: 1913645
[TBL] [Abstract] [Full Text] [Related]
